NeuroQore, Inc., is set to commercialize a new patented monophasic repetitive transcranial magnetic stimulation (rTMS) system with an improved remission rate. The first unit of the NeuroQore rTMS system was installed at the Royal Ottawa Mental Health Centre in July 2015 and successfully passed tolerability testing on healthy volunteers in a pilot project. The company is now in the midst of recruiting patients for the next round of testing. Preliminary clinical data is promising and has prompted installation of more units.
What Makes NeuroQore Different?
NeuroQore, Inc. offers the world's first monophasic rTMS therapy system. This system is a rapid and serious alternative for major depressive disorder, acute depression, and suicide. NeuroQore, Inc. offers dramatically reduced treatment times and immediate symptom relief. NeuroQore's unique approach allows patients to achieve remission within a few days.